HC Wainwright Has Bullish Forecast for RCUS FY2025 Earnings

Arcus Biosciences, Inc. (NYSE:RCUS) – Equities research analysts at HC Wainwright increased their FY2025 earnings per share (EPS) estimates for shares of Arcus Biosciences in a research note issued to investors on Wednesday, October 29th. HC Wainwright analyst E. Bodnar now anticipates that the company will post earnings per share of ($3.77) for the year, up from their prior forecast of ($3.83). HC Wainwright has a “Buy” rating and a $28.00 price objective on the stock. The consensus estimate for Arcus Biosciences’ current full-year earnings is ($3.15) per share. HC Wainwright also issued estimates for Arcus Biosciences’ FY2026 earnings at ($4.29) EPS, FY2027 earnings at ($4.46) EPS, FY2028 earnings at ($3.20) EPS and FY2029 earnings at ($1.85) EPS.

RCUS has been the topic of several other research reports. Wells Fargo & Company raised their target price on Arcus Biosciences from $25.00 to $29.00 and gave the stock an “overweight” rating in a research report on Monday, October 20th. Wall Street Zen lowered Arcus Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday. Truist Financial reissued a “buy” rating and set a $39.00 target price (up previously from $32.00) on shares of Arcus Biosciences in a research report on Tuesday, October 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Arcus Biosciences in a research report on Wednesday, October 8th. Finally, Citigroup raised their target price on Arcus Biosciences from $54.00 to $56.00 and gave the stock a “buy” rating in a research report on Wednesday. Seven equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $28.44.

Arcus Biosciences Price Performance

RCUS stock opened at $19.70 on Friday. The company has a debt-to-equity ratio of 0.22, a current ratio of 3.65 and a quick ratio of 4.50. The firm has a market capitalization of $2.13 billion, a P/E ratio of -5.73 and a beta of 0.77. The business’s 50-day moving average is $13.95 and its two-hundred day moving average is $10.73. Arcus Biosciences has a 1 year low of $6.50 and a 1 year high of $22.11.

Arcus Biosciences (NYSE:RCUS) last posted its quarterly earnings results on Tuesday, October 28th. The company reported ($1.27) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.33) by $0.06. The company had revenue of $26.00 million for the quarter, compared to analyst estimates of $19.89 million. Arcus Biosciences had a negative return on equity of 68.17% and a negative net margin of 136.40%.Arcus Biosciences’s revenue for the quarter was down 45.8% compared to the same quarter last year. During the same quarter last year, the company earned ($1.00) EPS.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in RCUS. GAMMA Investing LLC increased its position in Arcus Biosciences by 59.1% during the third quarter. GAMMA Investing LLC now owns 2,748 shares of the company’s stock worth $37,000 after buying an additional 1,021 shares during the period. CWM LLC increased its position in Arcus Biosciences by 233.6% during the second quarter. CWM LLC now owns 5,441 shares of the company’s stock worth $44,000 after buying an additional 3,810 shares during the period. Ameritas Investment Partners Inc. increased its position in Arcus Biosciences by 34.3% during the second quarter. Ameritas Investment Partners Inc. now owns 7,038 shares of the company’s stock worth $57,000 after buying an additional 1,796 shares during the period. PNC Financial Services Group Inc. grew its stake in shares of Arcus Biosciences by 440.3% in the 2nd quarter. PNC Financial Services Group Inc. now owns 7,597 shares of the company’s stock valued at $62,000 after purchasing an additional 6,191 shares during the last quarter. Finally, Strs Ohio acquired a new position in shares of Arcus Biosciences in the first quarter valued at approximately $67,000. Institutional investors and hedge funds own 92.89% of the company’s stock.

Insider Transactions at Arcus Biosciences

In other Arcus Biosciences news, President Juan C. Jaen sold 77,840 shares of Arcus Biosciences stock in a transaction that occurred on Wednesday, October 29th. The stock was sold at an average price of $20.90, for a total transaction of $1,626,856.00. Following the transaction, the president owned 1,091,374 shares of the company’s stock, valued at $22,809,716.60. The trade was a 6.66% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CAO Alexander Azoy sold 2,831 shares of Arcus Biosciences stock in a transaction that occurred on Monday, September 29th. The stock was sold at an average price of $13.00, for a total value of $36,803.00. Following the transaction, the chief accounting officer directly owned 27,363 shares in the company, valued at approximately $355,719. This trade represents a 9.38% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 156,561 shares of company stock worth $2,916,931. 9.60% of the stock is currently owned by corporate insiders.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.